These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 19509162

  • 1. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.
    Oostendorp RL, Huitema A, Rosing H, Jansen RS, Ter Heine R, Keessen M, Beijnen JH, Schellens JH.
    Clin Cancer Res; 2009 Jun 15; 15(12):4228-33. PubMed ID: 19509162
    [Abstract] [Full Text] [Related]

  • 2. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Int J Cancer; 2013 May 15; 132(10):2439-47. PubMed ID: 23090875
    [Abstract] [Full Text] [Related]

  • 3. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.
    Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW, Schot ME, Schellens JH.
    J Clin Oncol; 2001 Feb 15; 19(4):1160-6. PubMed ID: 11181682
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.
    Koolen SL, Oostendorp RL, Beijnen JH, Schellens JH, Huitema AD.
    Br J Clin Pharmacol; 2010 May 15; 69(5):465-74. PubMed ID: 20573082
    [Abstract] [Full Text] [Related]

  • 5. A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development.
    Yu H, Janssen JM, Sawicki E, van Hasselt JGC, de Weger VA, Nuijen B, Schellens JHM, Beijnen JH, Huitema ADR.
    J Clin Pharmacol; 2020 Mar 15; 60(3):340-350. PubMed ID: 31595980
    [Abstract] [Full Text] [Related]

  • 6. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
    Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, van Tellingen O.
    Cancer Res; 2002 Nov 01; 62(21):6158-64. PubMed ID: 12414642
    [Abstract] [Full Text] [Related]

  • 7. Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment.
    Loos NHC, Bui V, de Jong DH, Lebre MC, Rosing H, Beijnen JH, Schinkel AH.
    Cancer Chemother Pharmacol; 2024 Jul 01; 94(1):79-87. PubMed ID: 38456955
    [Abstract] [Full Text] [Related]

  • 8. A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir.
    de Weger VA, Stuurman FE, Koolen SLW, Moes JJ, Hendrikx JJMA, Sawicki E, Thijssen B, Keessen M, Rosing H, Mergui-Roelvink M, Huitema ADR, Nuijen B, Beijnen JH, Schellens JHM, Marchetti S.
    Clin Cancer Res; 2019 Sep 15; 25(18):5466-5474. PubMed ID: 31217201
    [Abstract] [Full Text] [Related]

  • 9. Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours.
    Vermunt MAC, de Weger VA, Janssen JM, Lopez-Yurda MI, Keessen M, Thijssen B, Rosing H, Huitema ADR, Beijnen JH, Marchetti S.
    Drugs R D; 2021 Mar 15; 21(1):103-111. PubMed ID: 33464545
    [Abstract] [Full Text] [Related]

  • 10. A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.
    de Weger VA, Stuurman FE, Hendrikx JJMA, Moes JJ, Sawicki E, Huitema ADR, Nuijen B, Thijssen B, Rosing H, Keessen M, Mergui-Roelvink M, Beijnen JH, Schellens JHM, Marchetti S.
    Eur J Cancer; 2017 Nov 15; 86():217-225. PubMed ID: 29031170
    [Abstract] [Full Text] [Related]

  • 11. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
    Kuppens IE, Bosch TM, van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2005 Jan 15; 55(1):72-8. PubMed ID: 15316750
    [Abstract] [Full Text] [Related]

  • 12. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.
    Hendrikx JJ, Lagas JS, Wagenaar E, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Br J Cancer; 2014 May 27; 110(11):2669-76. PubMed ID: 24781280
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.
    Vermunt MAC, van der Heijden LT, Hendrikx JJMA, Schinkel AH, de Weger VA, van der Putten E, van Triest B, Bergman AM, Beijnen JH.
    Cancer Chemother Pharmacol; 2021 Jun 27; 87(6):855-869. PubMed ID: 33744986
    [Abstract] [Full Text] [Related]

  • 14. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
    van Waterschoot RA, Lagas JS, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2010 Dec 15; 127(12):2959-64. PubMed ID: 21351274
    [Abstract] [Full Text] [Related]

  • 15. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
    Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH.
    Mol Pharmacol; 2001 Apr 15; 59(4):806-13. PubMed ID: 11259625
    [Abstract] [Full Text] [Related]

  • 16. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
    Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, Taguchi H, Koeffler HP.
    Cancer Res; 2004 Oct 15; 64(20):7426-31. PubMed ID: 15492266
    [Abstract] [Full Text] [Related]

  • 17. Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.
    Yu H, Hendrikx JJ, Rottenberg S, Schellens JH, Beijnen JH, Huitema AD.
    AAPS J; 2016 Mar 15; 18(2):362-71. PubMed ID: 26603889
    [Abstract] [Full Text] [Related]

  • 18. Oral delivery of taxanes.
    Malingré MM, Beijnen JH, Schellens JH.
    Invest New Drugs; 2001 May 15; 19(2):155-62. PubMed ID: 11392449
    [Abstract] [Full Text] [Related]

  • 19. Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer.
    Dandamudi UB, Adams LM, Johnson B, Bauman J, Morris S, Murray S, Webb RT, Gartner E, Hohl R, Lewis LD.
    Cancer Chemother Pharmacol; 2011 Apr 15; 67(4):783-90. PubMed ID: 20556613
    [Abstract] [Full Text] [Related]

  • 20. Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice.
    Hudachek SF, Gustafson DL.
    Anticancer Drugs; 2013 Oct 15; 24(9):958-68. PubMed ID: 23928571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.